FDA Used Incomplete Data To Justify Deregulation of Chemical Abortion Pills, Studies Show

The Food and Drug Administration relied on incomplete data to reach its determination that it is safe to deregulate chemical abortion pills, according to medical studies.

FDA officials brushed aside concerns that women who obtain chemical abortion pills without an in-person doctor visit might put their health at risk. The agency did so by pointing to its Adverse Event Reporting System, which catalogues deaths and other side effects from abortion drugs like mifepristone.